RxDoctor Payments Data

Reshma Bhanushali, MD

Internal Medicine · Lafayette, LANPI 1285892182

Payments from drug & device makers

$6,221in general payments, 2019–2025

Across 372 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$905
  • Lilly USA, LLC$826
  • Pfizer$553
  • Amgen$495
  • Novartis$487
  • AstraZeneca$470
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$6,16899%
  • Education$531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,221 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$133,839
Medicare patients
428
Services billed
1,520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide136$162,679
EliquisApixaban99$85,203
XareltoRivaroxaban47$45,151
JardianceEmpagliflozin27$44,848
FarxigaDapagliflozin Propanediol31$41,882
TrulicityDulaglutide25$26,539
OzempicSemaglutide27$24,879
LinzessLinaclotide15$12,776
JanuviaSitagliptin Phosphate16$11,581
Tresiba Flextouch U-100Insulin Degludec17$10,171
Breo ElliptaFluticasone/Vilanterol17$7,603
VascepaIcosapent Ethyl21$7,031
TrintellixVortioxetine Hydrobromide12$5,712
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,648
Metoprolol Succinate240$3,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$826$189,218161 claims
PfizerEliquis$553$85,20399 claims
Johnson & JohnsonXarelto$196$45,15147 claims
Boehringer IngelheimJardiance$165$44,84827 claims
AstraZenecaFarxiga$470$41,88231 claims
Novo NordiskOzempic$310$24,87927 claims
AbbVieLinzess, Synthroid$905$15,26753 claims
MerckJanuvia$32$11,58116 claims
GSKBreo Ellipta$166$7,60317 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$317$5,71212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →